Hugo M. Horlings

25.3k citations

109 papers · 12.0k indexed · 5 hit papers · h-index 39

Cancer Research top 0.1%
- Cancer Genomics and Diagnostics 18
- Breast Cancer Treatment Studies 16
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 26
- Cancer Cells and Metastasis 19
- HER2/EGFR in Cancer Research 15
Molecular Biology top 0.5%
- Gene expression and cancer classification 11
Immunology top 2%
Pathology and Forensic Medicine top 1%
Artificial Intelligence
- AI in cancer detection 10
Reproductive Medicine
- Ovarian cancer diagnosis and treatment 8

Co-authors: Marc J. van de Vijver Howard Y. Chang Tiffany Hung Rui Li Robert B. West Miao-Chih Tsai Pedram ArganiKe Wang
Cited by: Cancer Research Oncology Molecular Biology
Journals: Nature (2 papers)Cell (2 papers)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: Netherlands United States Belgium

In The Last Decade

Hugo M. Horlings

103 papers receiving 11.9k citations

Hit Papers

5 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2018 Cell
2017 Nature
2010 Nature
2009 Proceedings of the National Academy of Sciences
2007 Cancer Cell

Peers

Countries citing papers authored by Hugo M. Horlings

Since Specialization

Citations

This map shows the geographic impact of Hugo M. Horlings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugo M. Horlings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugo M. Horlings more than expected).

Fields of papers citing papers by Hugo M. Horlings

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugo M. Horlings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugo M. Horlings. The network helps show where Hugo M. Horlings may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hugo M. Horlings, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hugo M. Horlings Line = papers co-authored together Hugo M. Horlings links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Foundation Models in Medical Imaging: A Review and Outlook ArXiv.org ·Vivien van Veldhuizen,Vanessa Botha,Chunyao Lu,Melis Erdal Cesur,Kevin Groot Lipman,Edwin D. de Jong,Hugo M. Horlings,Clarisa Sánchez,Cees G. M. Snoek,Lodewyk F.A. Wessels,Ritse M. Mann,Eric Marcus,Jonas Teuwen	2025	0
2	Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass International Journal of Gynecological Cancer ·Duco Gaillard,Pien Lof,Erik A. Sistermans,Tom Mokveld,Hugo M. Horlings,Constantijne H. Mom,Marcel Reinders,Frédéric Amant,Daan van den Broek,Lodewyk F.A. Wessels,Christianne Lok,Marco van Gent,Majoie Hemelaar,WM van Baal,M.B. Verbruggen,F Rosier-van Dunné,BBJ Hermse	2024	3
3	Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade npj Breast Cancer ·Marte C. Liefaard,Anna van der Voort,Maartje van Seijen,Bram Thijssen,Joyce Sanders,Shiva Vonk,Lorenza Mittempergher,Rajith Bhaskaran,Linda de Munck,A. Elise van Leeuwen‐Stok,Roberto Salgado,Hugo M. Horlings,Esther H. Lips,Gabe S. Sonke	2024	10
4	An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer Nature Communications ·Yuan Gao,Sofía Ventura‐Díaz,Xin Wang,Muzhen He,Zeyan Xu,Alva B. Weir,Hong-Yu Zhou,Tianyu Zhang,Frederieke van Duijnhoven,Luyi Han,Xiao‐Mei Li,Anna D’Angelo,Valentina Laurita Longo,Zaiyi Liu,Jonas Teuwen,Marleen Kok,Regina G. H. Beets‐Tan,Hugo M. Horlings,Tao Tan,Ritse M. Mann	2024	24
5	Does “One Size Fits All”? Rethinking FIGO Depth of Invasion Measurements in Vulvar Cancer International Journal of Gynecological Pathology ·Maaike C.G. Bleeker,Tjalling Bosse,Koen Van de Vijver,Joost Bart,Hugo M. Horlings,Trudy Jonges,Nicole C.M. Visser,Loes Kooreman,Johan Bulten,Patricia C. Ewing‐Graham	2024	0
6	Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort JCO Precision Oncology ·Tessa G. Steenbruggen,Denise M. Wolf,Bram Thijssen,Joyce Sanders,Sten Cornelissen,Roberto Salgado,Lorenza Mittempergher,Rajith Bhaskaran,Annegien Broeks,Esther H. Lips,Sabine Siesling,Gabe S. Sonke,Hugo M. Horlings,Laura van ‘t Veer	2023	1
7	Characteristics of long-term survival in advanced stage ovarian cancer: a nationwide cohort in the Netherlands European Journal of Gynaecological Oncology ·Lilian van Wagensveld,Gabe S. Sonke,(unknown),Hugo M. Horlings,(unknown),M Pétrus	2022	0
8	Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer npj Breast Cancer ·Iris Nederlof,S. Hajizadeh,Faranak Sobhani,Shan E Ahmed Raza,Khalid AbdulJabbar,Rolf Harkes,Marc J. van de Vijver,Roberto Salgado,Christine Desmedt,M. Kok,Yinyin Yuan,Hugo M. Horlings	2022	8
9	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer JNCI Cancer Spectrum ·Tessa G. Steenbruggen,Michael Schaapveld,Hugo M. Horlings,Joyce Sanders,Sander J Hogewoning,Esther H. Lips,Marie-Jeanne TFD Vrancken Peeters,Niels F. M. Kok,T. Wiersma,Laura J. Esserman,Laura van ‘t Veer,Sabine C. Linn,Sabine Siesling,Gabe S. Sonke	2021	18
10	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer Nature Communications ·Dora Hammerl,John W.M. Martens,Mieke Timmermans,Marcel Smid,Anita Trapman-Jansen,Renée Foekens,Olga I. Isaeva,Leonie Voorwerk,Hayri E. Balcıoğlu,Rebecca Wijers,Iris Nederlof,Roberto Salgado,Hugo M. Horlings,Marleen Kok,Reno Debets	2021	135
11	The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers Molecular Cancer Research ·Irida Kastrati,Stacey E. P. Joosten,Svetlana E. Semina,Luis H. Alejo,Svitlana D. Brovkovych,Joshua D. Stender,Hugo M. Horlings,Marleen Kok,Elaine T. Alarid,Geoffrey L. Greene,Sabine C. Linn,Wilbert Zwart,Jonna Frasor	2020	38
12	Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy European Journal of Cancer ·Leonora W. de Boo,Ashley Cimino‐Mathews,Yoni Lubeck,Antonios Daletzakis,Mark Opdam,Joyce Sanders,Erik Hooijberg,Annelot van Rossum,Zuzana Loncová,Dietmar Rieder,Zlatko Trajanoski,Marieke A. Vollebergh,Marcelo Sobral‐Leite,Koen Van de Vijver,Annegien Broeks,R Wiel,Harm van Tinteren,Sabine C. Linn,Hugo M. Horlings,Marleen Kok	2020	18
13	The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·J. O. A. M. van Baal,Christianne Lok,Ekaterina S. Jordanova,Hugo M. Horlings,Willemien J. van Driel,Frédéric Amant,Koen Van de Vijver	2020	8
14	Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial Annals of Oncology ·Marleen Kok,Hugo M. Horlings,K. Van de Vijver,T. Wiersma,Nicola S. Russell,Leonie Voorwerk,Karolina Sikorska,Erik van Werkhoven,Ingrid A.M. Mandjes,Inge Kemper,J. Foekema,Sofie Wilgenhof,Myriam Chalabi,Jacqueline M. Stouthard,Gabe S. Sonke,Dana Cullen,Roberto Salgado,Ton N. Schumacher,Christian U. Blank,SC Linn	2017	21
15	Retrospective analysis of metastatic behaviour of breast cancer subtypes Breast Cancer Research and Treatment ·C. Dilara Savci‐Heijink,Hans Halfwerk,Gerrit K. Hooijer,Hugo M. Horlings,Jelle Wesseling,Marc J. van de Vijver	2015	129
16	Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary Gynecologic Oncology ·Hannah S. van Meurs,Ewoud Schuit,Hugo M. Horlings,Jacobus van der Velden,Willemien J. van Driel,Ben W. Mol,Gemma G. Kenter,Marrije R. Buist	2014	19
17	MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing Cancer Research ·Thalia A. Farazi,Hugo M. Horlings,Jelle J. ten Hoeve,Aleksandra Mihailović,Hans Halfwerk,Pavel Morozov,Miguel Brown,Markus Hafner,Fabien Reyal,Marieke van Kouwenhove,Bas Kreike,Daoud Sie,Volker Hovestadt,Lodewyk F.A. Wessels,Marc J. van de Vijver,Thomas Tuschl	2011	275
18	Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients Clinical Cancer Research ·Hugo M. Horlings,Carmen Lai,Dimitry S.A. Nuyten,Hans Halfwerk,Petra Kristel,Erik van Beers,Simon A. Joosse,Christiaan Klijn,Petra M. Nederlof,Marcel Reinders,Lodewyk F.A. Wessels,Marc J. van de Vijver	2010	48
19	Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasisbreakdown → Nature ·Rajnish A. Gupta,Nilay Shah,Ke Wang,Jeewon Kim,Hugo M. Horlings,David J. Wong,Miao-Chih Tsai,Tiffany Hung,Pedram Argani,John L. Rinn,Yulei Wang,Pius Brzoska,Benjamin Kong,Rui Li,Robert B. West,Marc J. van de Vijver,Saraswati Sukumar,Howard Y. Chang	2010	4231
20	Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer Clinical Cancer Research ·Paul Roepman,Hugo M. Horlings,Oscar Krijgsman,Marleen Kok,Jolien M. Bueno-de-Mesquita,Richard A. Bender,Sabine C. Linn,Annuska M. Glas,Marc J. van de Vijver	2009	75

About Hugo M. Horlings

Hugo M. Horlings is a scholar working on Cancer Research, Oncology and Reproductive Medicine, having authored 109 papers that have together received 12.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (26 papers), Cancer Cells and Metastasis (19 papers), Cancer Genomics and Diagnostics (18 papers), Breast Cancer Treatment Studies (16 papers), HER2/EGFR in Cancer Research (15 papers), Gene expression and cancer classification (11 papers), AI in cancer detection (10 papers) and Ovarian cancer diagnosis and treatment (8 papers). The work is most often cited by research in Cancer Research (6.0k citations), Oncology (4.2k citations) and Molecular Biology (7.5k citations). Hugo M. Horlings has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Marc J. van de Vijver, Howard Y. Chang, Tiffany Hung, Rui Li, Robert B. West, Miao-Chih Tsai, Pedram Argani, Ke Wang, Nilay Shah and Yulei Wang. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact